Rhythm Technologies announced new research emphasizing the clinical and health-economic advantages of its Zio LTCM system.

At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

Using an artificial intelligence program to read echocardiograms may reduce the wait time for results and help lead to more ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Artificial intelligence is making impressive strides in its ability to read medical images. In a recent test in Britain's ...

After treatment with white button mushroom extract in mice and patients with prostate cancer, scientists discovered a decline ...

In the first ever human clinical study, replacing refined sugars with the same amount of pure maple syrup for 5% of daily energy intake resulted in improved glycemic response, lower systolic blood ...

University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, alleviates symptoms ...

Two papers published in Journal of Orthopaedic Research Spine show the promise of PP353 through preclinical development and ...

during a clinical test, all without drawing blood. Instead, they used a device they had developed in 2016 that features a ...

Artificial intelligence is making impressive strides in its ability to read medical images. In a recent test in Britain's National Health Service, an ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...